Eupraxia Pharmaceuticals (EPRX) Selling, General & Administrative (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted Selling, General & Administrative of $5.3 million for the quarter ended Jun 30, 2026, up 72.7% from $3.07 million a year earlier and up 10.8% from the prior quarter.
Eupraxia Pharmaceuticals (EPRX) Selling, General & Administrative (2023 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Selling, General & Administrative at Eupraxia Pharmaceuticals was $20.84 million, up 71.3% year-over-year; for the year ended Dec 31, 2025, it was $17.1 million, up 56.6% from the prior year.
- Annual Selling, General & Administrative has increased for three consecutive years, with a three-year compound annual growth rate of 62.5% (years ended Dec 2022 to Dec 2025).
- In prior years, Eupraxia Pharmaceuticals' Selling, General & Administrative was $10.92 million in the year ended Dec 31, 2024 (+46.0%), $7.48 million in the year ended Dec 31, 2023 (+87.7%) and $3.99 million in the year ended Dec 31, 2022.
- Quarterly Selling, General & Administrative has run from a low of $1.26 million in the quarter ended Mar 31, 2023 to a high of $8.3 million in the quarter ended Dec 31, 2025 over five years.
- On a year-over-year basis, Selling, General & Administrative has increased in each of the last ten quarters, with growth averaging 47.0% over the last eight quarters.
- Over the past five years, the year-over-year growth in Selling, General & Administrative ranged from 10.9% (the quarter ended Sep 30, 2025) to 130.4% (the quarter ended Dec 31, 2025).
- According to Business Quant data, Selling, General & Administrative for the three prior quarters was $4.78 million (quarter ended Mar 31, 2026), $8.3 million (quarter ended Dec 31, 2025) and $2.47 million (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 3.43 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 6.43 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 3.63 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 2.90 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | -3.24 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | -5.65 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 1.75 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 1.92 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 3.41 Bn |
| 10 | Eupraxia Pharmaceuticals | 312.86 Mn | 311.25 Mn | - | 5.30 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.30 Mn |
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 8.30 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.27 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.52 Mn |
| Dec 31, 2023 | 2.44 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.26 Mn |
Eupraxia Pharmaceuticals Selling, General & Administrative API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "selling-general-and-administrative", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();